Abstract
The scale of data produced during the SARS-CoV-2 pandemic has been unprecedented, with more than 5 million sequences shared publicly at the time of writing. This wealth of sequence data provides important context for interpreting local outbreaks. However, placing sequences of interest into national and international context is difficult given the size of the global dataset. Often outbreak investigations and genomic surveillance efforts require running similar analyses again and again on the latest dataset and producing reports. We developed civet (cluster investigation and virus epidemiology tool) to aid these routine analyses and facilitate virus outbreak investigation and surveillance. Civet can place sequences of interest in the local context of background diversity, resolving the query into different ’catchments’ and presenting the phylogenetic results alongside metadata in an interactive, distributable report. Civet can be used on a fine scale for clinical outbreak investigation, for local surveillance and cluster discovery, and to routinely summarise the virus diversity circulating on a national level. Civet reports have helped researchers and public health bodies feedback genomic information in the appropriate context within a timeframe that is useful for public health.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AOT is supported by the Wellcome Trust Hosts, Pathogens & Global Health Programme (grant number: grant.203783/Z/16/Z) and Fast Grants (award number: 2236). V.H. is supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (grant number BB/M010996/1). AR, RC, JTM acknowledge support from the Wellcome Trust (Collaborators Award 206298/Z/17/Z ARTIC network). AR is supported by the European Research Council (grant agreement no. 725422 ReservoirDOCS) and the Bill & Melinda Gates Foundation (OPP1175094 HIV-PANGEA II). AOT, VH and BJ acknowledge funding from COVID-19 Genomics UK Consortium (COG-UK), UK Department of Health and Social Care, UK Research and Innovation. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute. IG is a Wellcome Senior Fellow and is supported by funding from the Wellcome Trust (ref: 207498/Z/17/Z and 206298/B/17/Z). NS, CVFC and the COVID-19 Impact Project acknowledge funding from the Trinidad and Tobago - UWI Research Development Impact Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the scenarios presented as example cases for civet use are synthethic examples inspired by actual data and details have been entirely anonymised and/or altered. The first case study is constructed outbreak loosely based on a hospital outbreak, but details have been masked. The second case study uses only publically available data from COG-UK. The UK studies were done as part of surveillance for COVID-19 infections under the auspices of Section 251 of the National Health Service Act 2006 or Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002, or both. They therefore did not require individual patient consent or ethical approval. The COVID-19 Genomics UK Consortium study protocol was approved by the Public Health England Research Ethics Governance Group (reference number R&D NR0195). The third case study in Trinidad and Tobago is wholly based on public data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵‡ Full list of consortium names and affiliations are in the appendix
